Addressing drug development for rare pediatric cancers, the newly released FDA draft guidance for industry calls for creating pediatric cohorts, embedding pediatric trials in adult trials, lowering the enrollment age for adolescents, conducting tissue-agnostic studies and master protocols.
The guidance has links to lists of relevant molecular targets for which pediatric studies are required, and those that are non-relevant to pediatric cancers.